Trojan Horse‐Like Biohybrid Nanozyme for Ameliorating Liver Ischemia‐Reperfusion Injury
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Dao-Feng Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Liver, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xinqiao Hospital Young Doctor Incubation Program.
Abstract (Originalsprache)
Liver ischemia and reperfusion (I/R) injury is a reactive oxygen species (ROS)‐related disease that occurs during liver transplantation and resection and hinders postoperative liver function recovery. Current approaches to alleviate liver I/R injury have limited effectiveness due to the short circulation time, poor solubility, and severe side effects of conventional antioxidants and anti‐inflammatory drugs. Herein, a universal strategy is proposed to fabricate a Trojan horse‐like biohybrid nanozyme (THBN) with hepatic‐targeting capabilities. Tannic acid (TA) mediates adeno‐associated virus (AAV8) decoration onto 2D Ti 3 C 2 nanosheets, resulting in THBN with a size of 116.2 ± 9.5 nm. Remarkably, THBN exhibits catalase (CAT)‐like activity, broad‐spectrum ROS scavenging activity and targeted delivery to liver tissue owing to the presence of AAV8. Both in vivo and in vitro experiments confirmed the efficacy of THBN in attenuating liver I/R injury by mitigating inflammation and oxidative stress and inhibiting hepatocellular apoptosis. RNA‐seq analysis suggests that THBN may alleviate liver I/R injury by activating the PKC pathway. The effective targeting and therapeutic capabilities of THBN represent an advancement in nanotherapeutics for hepatic ischemia‒reperfusion injury, shedding light on the promising potential of this next‐generation nanotherapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
- Department of Ultrasound, Medical Research Center, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, 610031, China.
- College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, Sichuan, 610065, China.
ORCID-Profile: Wei-Dong Xiao
Förderung
- National Natural Science Foundation of China
- Xinqiao Hospital Young Doctor Incubation Program
Zitieren
APA
Zheng, D. F., Zha, X. J., Jiang, E. L., Qiu, Y., Yang, W., & Xiao, W. D. (2025). Trojan Horse‐Like Biohybrid Nanozyme for Ameliorating Liver Ischemia‐Reperfusion Injury. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404458
Vancouver
Zheng DF, Zha XJ, Jiang EL, Qiu Y, Yang W, Xiao WD. Trojan Horse‐Like Biohybrid Nanozyme for Ameliorating Liver Ischemia‐Reperfusion Injury. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404458
BibTeX
@article{Zheng2025,
author = {Zheng, Dao-Feng and Zha, Xiang-Jun and Jiang, En-Lai and Qiu, Yuan and Yang, Wei and Xiao, Wei-Dong},
title = {Trojan Horse‐Like Biohybrid Nanozyme for Ameliorating Liver Ischemia‐Reperfusion Injury},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404458}
}
EUVIMED